Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV005003119 | SCV005631192 | uncertain significance | Focal segmental glomerulosclerosis 6 | 2024-01-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV005377684 | SCV006038718 | uncertain significance | Inborn genetic diseases | 2025-01-17 | criteria provided, single submitter | clinical testing | The c.3100A>G (p.S1034G) alteration is located in exon 27 (coding exon 27) of the MYO1E gene. This alteration results from a A to G substitution at nucleotide position 3100, causing the serine (S) at amino acid position 1034 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |